LUMRYZ Drives 27% Revenue Surge for Alkermes, but Acquisition Costs and Debt Push Q2 Profit to Near Breakeven
ALKS sits 95% above its 52-week low of $25.165.
Summary
Alkermes' Q2 2026 revenue surged 27% to $496 million with the addition of LUMRYZ, but acquisition-related costs pushed net income to just $0.5 million. Full-year guidance was revised to a wider GAAP loss and lower EBITDA.
Key Events · Earnings and Guidance · ALKS
-
Q2 Revenue Up 27%, Net Income Near Breakeven
Driven by $96.6 million in LUMRYZ sales, total revenues rose to $496.0 million from $390.7 million a year ago. Net income was $0.5 million, or $0.00 per share, as $180 million in higher operating expenses and $25.9 million in new interest expense offset the revenue gain.
-
Acquisition Costs Weigh on Profitability
Cost of goods sold included $31.0 million in inventory step-up amortization, and a $26.4 million non-cash charge was recorded for the increase in fair value of contingent consideration after positive REVITALYZ Phase 3 data for LUMRYZ in idiopathic hypersomnia.
-
Full-Year Guidance Revised Lower
Alkermes updated its 2026 outlook to a wider GAAP net loss and lower EBITDA, reflecting the ongoing impact of acquisition accounting and integration costs.
-
Balance Sheet Transformed by Avadel Deal
Total assets doubled to $4.4 billion, including $1.76 billion in intangible assets and $594 million in goodwill. Long-term debt of $1.5 billion was added to fund the acquisition, with $26.5 million due within a year.
Analysis · ALKS · Life Sciences
Top-line momentum was unmistakable in Q2 2026, as the addition of LUMRYZ following the Avadel acquisition propelled revenue sharply higher. Yet the benefits were largely consumed by acquisition-related costs — amortization of inventory step-up, intangible amortization, and a $26.4 million non-cash charge from revaluing contingent consideration upward after positive LUMRYZ Phase 3 data. The net result was income of just $0.5 million. The balance sheet has been transformed: total assets doubled to $4.4 billion, but long-term debt now stands at $1.5 billion. Full-year guidance was also updated to a wider GAAP net loss and lower EBITDA, signaling that integration costs will continue to pressure profitability. On the legal front, a favorable appellate ruling in the Acorda matter removes a $66 million overhang, while new ANDA litigation against Apotex adds uncertainty for LYBALVI. Three officers adopted 10b5-1 trading plans, a routine but notable disclosure.
At the time of this filing, ALKS was trading at $49.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8B. The 52-week trading range was $25.17 to $55.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.